Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

https://doi.org/10.1182/blood-2019-125884

Published: 2019

Journal Articles

Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia

Shuyu E, Aman Seth, Peter Vogel, Matt Sommers, Taren Ong, Asha B. Pillai

Blood (2017) 129 (22): 3017–3030.

https://doi.org/10.1182/blood-2016-03-704387

Published: 2017

Includes: Supplemental data

Journal Articles

Host natural killer T cells induce an interleukin-4–dependent expansion of donor CD4 + CD25 + Foxp3 + T regulatory cells that protects against graft-versus-host disease

Asha B. Pillai, Tracy I. George, Suparna Dutt, Samuel Strober

Blood (2009) 113 (18): 4458–4467.

https://doi.org/10.1182/blood-2008-06-165506

Published: 2009

Includes: Supplemental data

Journal Articles

Interaction between Host Natural Killer T Cells and Donor CD4 + CD25 + T reg Cells Protects Against GVHD after TLI/ATS Host Conditioning and Bone Marrow Transplantation.

Asha B. Pillai, MD, Suparna Dutt, Ph.D., Tracy I. George, M.D., Samuel A. Strober, M.D.

Blood (2006) 108 (11): 445.

https://doi.org/10.1182/blood.V108.11.445.445

Published: 2006

Journal Articles

Donor CD8+ T Cells Facilitate Graft-Versus-Tumor Effect Via Alloantigen Rather Than Tumor-Specific Antigen Recognition Following Murine Myeloablative BMT.

Asha B. Pillai, MD, Pearline A. Teo, BS, Aditi Mukhopadhyay, BS, Samuel Strober, MD

Blood (2004) 104 (11): 3051.

https://doi.org/10.1182/blood.V104.11.3051.3051

Published: 2004

NARROW

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia

Host natural killer T cells induce an interleukin-4–dependent expansion of donor CD4 + CD25 + Foxp3 + T regulatory cells that protects against graft-versus-host disease

Interaction between Host Natural Killer T Cells and Donor CD4 + CD25 + T reg Cells Protects Against GVHD after TLI/ATS Host Conditioning and Bone Marrow Transplantation.

Donor CD8+ T Cells Facilitate Graft-Versus-Tumor Effect Via Alloantigen Rather Than Tumor-Specific Antigen Recognition Following Murine Myeloablative BMT.

Email alerts

ASH Publications

American Society of Hematology

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia

Host natural killer T cells induce an interleukin-4–dependent expansion of donor CD4 + CD25 + Foxp3 + T regulatory cells that protects against graft-versus-host disease

Interaction between Host Natural Killer T Cells and Donor CD4 + CD25 + T reg Cells Protects Against GVHD after TLI/ATS Host Conditioning and Bone Marrow Transplantation.

Donor CD8+ T Cells Facilitate Graft-Versus-Tumor Effect Via Alloantigen Rather Than Tumor-Specific Antigen Recognition Following Murine Myeloablative BMT.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only